Mansi Saxena, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses findings from a Phase I trial (NCT02721043) on the immunogenicity of PGV_001 neoantigen vaccine across various types of cancers in adjuvant setting. The primary outcome measures were dose-limiting toxicities and toxicity grading using CTCAE scale. Analysis revealed all patients responded to at least one neoantigen, and a majority had a robust immune response. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
